Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma - Pisula, Juan I.; Helbig, Doris; Sancéré, Lucas; Persa, Oana-Diana; Bürger, Corinna; Fröhlich, Anne; Lorenz, Carina; Bingmann, Sandra; Niebel, Dennis; Drexler, Konstantin; Landsberg, Jennifer; Thomas, Roman; et al. (medRxiv, 2024)
Predicting cancer patient disease progression is a key step towards personalized medicine and secondary prevention. The ability to predict which patients are at an elevated risk of developing local recurrences or metastases would allow for tailored surveillance of these high-risk patients as well as enhanced and timely interventions.We developed a deep learning transformer-based approach for prediction of progression of cutaneous squamous cell carcinoma (cSCC) patients based on diagnostic histopathology slides of the tumor. Our model, trained in a federated manner on patient cohorts from three clinical centers, reached an accuracy of AUROC=0.82, surpassing the predictive power of clinico-pathological parameters used to assess progression risk. We conducted an interpretability analysis, systematically comparing a broad range of spatial and morphological features that characterize tissue regions predictive of patient progression. Our findings suggest that information located at the tumor boundaries is predictive of patient progression and that heterogeneity of tissue morphology and organization are characteristic of progressive cSCCs. Trained in a federated fashion exclusively on standard diagnostic slides obtained during routine care of cSCC patients, our model can be deployed and expanded across other clinical centers. This approach thereby offers a potentially powerful tool for improved screening and thus better clinical management of cSCC patients.Competing Interest StatementD.N. received financial support (speaker s honoraria, advisory boards, travel expense reimbursements or grants) from Abbvie, Almirall, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers-Squib, GlaxoSmithKline, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Lilly, L Oreal/Cerave, MSD, Novartis, Pfizer, Regeneron and UCB Pharma. J.B. received research funding from Bayer outside the presented work. K.D. received financial support (speaker s honoraria, advisory boards, travel expense reimbursements or grants) from Abbvie, Bristol-Myers-Squib, Novartis, and Pierre-Fabre.Funding StatementA.F. was partly funded by the Deutsche Krebshilfe through a Mildred Scheel Foundation Grant (grant number 70113307). C.L. was partly funded through the collaborative research center grant on small cell lung cancer (CRC1399, project ID 413326622) by the German Research Foundation (DFG). Both K.B. and J.I.P. were hosted by the Center for Molecular Medicine Cologne throughout this research. K.B. and J.I.P. were supported by the BMBF program Junior Group Consortia in Systems Medicine (01ZX1917B) and BMBF program for Female Junior Researchers in Artificial Intelligence (01IS20054).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs of University Hospital Cologne (Department of Dermatology), University Hospital Bonn (Department of Dermatology and Department of Oral and Maxillo-facial Surgery, Technical University Munich (Department of Dermatology) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.